New Zealand markets closed
  • NZX 50

    11,564.75
    -160.87 (-1.37%)
     
  • NZD/USD

    0.6234
    -0.0037 (-0.59%)
     
  • ALL ORDS

    7,085.10
    -103.10 (-1.43%)
     
  • OIL

    65.33
    -1.41 (-2.11%)
     
  • GOLD

    1,999.10
    +25.60 (+1.30%)
     

ImmunoGen Announces Webcasts of Presentations at Upcoming Conferences

WALTHAM, Mass., February 01, 2023--(BUSINESS WIRE)--ImmunoGen, Inc. (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced that the following presentations by Company management at upcoming investor conferences will be webcast:

  • Guggenheim Healthcare Talks 2023 Oncology Conference

February 9 at 3:20pm ET

  • SVB Securities Global Biopharma Conference

February 15 at 10:00am ET

A webcast of each presentation will be accessible through the "Investors and Media" section of the Company’s website, www.immunogen.com. Following the live webcast, a replay will be available at the same location.

ABOUT IMMUNOGEN

ImmunoGen is developing the next generation of antibody-drug conjugates (ADCs) to improve outcomes for cancer patients. By generating targeted therapies with enhanced anti-tumor activity and favorable tolerability profiles, we aim to disrupt the progression of cancer and offer our patients more good days. We call this our commitment to TARGET A BETTER NOW™.

Learn more about who we are, what we do, and how we do it at www.immunogen.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20230201005203/en/

Contacts

INVESTOR RELATIONS
ImmunoGen
Anabel Chan
781-895-0600
anabel.chan@immunogen.com

MEDIA
ImmunoGen
Courtney O'Konek
781-895-0600
courtney.okonek@immunogen.com

OR

FTI Consulting
Robert Stanislaro
212-850-5657
robert.stanislaro@fticonsulting.com